Pola-ZR2P in Previously Untreated DLBCL

Inclusion Criteria

• •Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
• •Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• •Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
• •Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
• •Patient has not received chemotherapy previously.
• •Anticipated life expectancy at least 3 months